Evidence map›Paper›PMID 38940676›Full record

ReviewExpert review of cardiovascular therapy2024

The role of statin therapy in older adults: best practices and unmet challenges.

John Stone, Manish Kumar, Ariela R Orkaby

Abstract readReview
In one paragraph

Review in Expert review of cardiovascular therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

John StoneDepartment of Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
Manish KumarAlbert Einstein College of Medicine, Montefiore Medical Center, New York, NY, USA.
Ariela R OrkabyNew England GRECC (Geriatric Research, Education, and Clinical Center), VA Boston Healthcare System, Division of Aging, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.

Funding

TUFTS--FIELDINGP30AG031679 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI Thomas Glenn Travison · 2008 to 2026
$23.9M
PREVENTABLE Frailty Ancillary StudyR01AG081287 · NIA · BOSTON VA RESEARCH INSTITUTE, INC. · PI ORKABY, ARIELA R · 2024 to 2025
$2.6M
Frailty, Statins, and Cardiovascular Disease Burden in Older AdultsR03AG060169 · NIA · HARVARD MEDICAL SCHOOL · PI ORKABY, ARIELA R · 2018 to 2019
$193k
Statins for Primary Prevention of Cardiovascular Disease and FrailtyIK2CX001800 · VA · VA BOSTON HEALTH CARE SYSTEM · PI ORKABY, ARIELA R · 2019 to 2023
–
CSRD VA IK2 CX001800NIA NIH HHS P30 AG031679NIA NIH HHS R01 AG081287NIA NIH HHS R03 AG060169
6 · The paper itself

Abstract

introductionCardiovascular disease (CVD) is associated with significant morbidity, functional decline, and mortality in older adults. The role of statins for primary CVD prevention in older adults remains unclear, largely due to systematic exclusion of these individuals in trials that inform current practice guidelines, leading to conflicting national and international practice recommendations for statin use for primary prevention of CVD in adults aged 75 and older. AREAS COVERED: In this narrative review, we performed a literature review utilizing PubMed, and ultimately focus on seven major national and international guidelines of lipid lowering therapy. Through the lens of two clinical cases, we review physiologic changes in lipid metabolism with aging, discuss the relationship between cholesterol and cardiovascular events in older adults, examine the national and international guidelines and the available evidence informing these guidelines for statin use in primary prevention of CVD in older adults. Finally we review practical clinical considerations for drug monitoring and deprescribing in this population. EXPERT OPINION: Guidelines for the use of statins for primary CVD prevention in older adults is conflicting. Collectively, evidence to date suggests statin therapy may be beneficial for primary CVD prevention in older adults free of life-limiting comorbidities. Randomized controlled trials are currently underway to address current evidence gaps.

Indexed as

Cardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase InhibitorsPractice Guidelines as TopicPrimary PreventionAgedAge FactorsCholesterolDrug MonitoringHumansLipid MetabolismRandomized Controlled Trials as TopicCholesterolHydroxymethylglutaryl-CoA Reductase Inhibitorscardiovascular diseaseelderlyfrailtypreventionStatins

Identifiers

PMID38940676
PMCPMC11331431

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.